Qiwei Ye

Mr. Qiwei Ye


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 December 2025 in Journal of Chemical Theory and Computation
Verified
Journal Article
Open access
XHXu Han
Xu Han
YSYuancheng Sun
Yuancheng Sun
KCKai Chen
Kai Chen
YRYuxuan Ren
Yuxuan Ren
KLKang Liu
Kang Liu
QYQiwei Ye
Qiwei Ye
Coarse-grained (CG) molecular dynamics simulations enable efficient exploration of protein conformational ensembles. However, reconstructing atomic details from CG structures (backmapping) remains a challenging problem. Current approaches face an inherent trade-off between maintaining atomistic accuracy and exploring diverse conformations, often necessitating complex constraint handling or extensive refinement steps. To address these challenges, we introduce a novel two-stage framework, named CODLAD (COnstraint Decoupled LAtent Diffusion). This framework first compresses atomic structures into discrete latent representations, explicitly embedding structural constraints, thereby decoupling constraint handling from generation. Subsequently, it performs efficient denoising diffusion in this latent space to produce structurally valid and diverse all-atom conformations. Comprehensive evaluations on diverse protein data sets demonstrate that CODLAD achieves state-of-the-art performance in atomistic accuracy, conformational diversity, and computational efficiency while exhibiting strong generalization across different protein systems.

25 September 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
KFKeke Fan
Keke Fan
YXYanan Xu
Yanan Xu
QYQiwei Ye
Qiwei Ye
MZMingliang Zeng
Mingliang Zeng
HXHongwang Xiao
Hongwang Xiao
LHLiming Hu
Liming Hu
Endpoint structure–activity relationships (SAR) for irreversible inhibitors can integrate reversible binding, covalent chemistry, conformational behavior, and cellular factors, making it difficult to assign a potency change to a single molecular event. We reanalyzed a previously reported series of irreversible inhibitors of wild-type (WT) HER2 and HER2 A775_G776insYVMA (HER2YVMA) as six matched analogue pairs. Three complementary analyses were kept physically distinct. Pre-reaction molecular dynamics (MD) trajectories were used to quantify the fraction of frames satisfying a predefined near-attack-conformation (NAC)-like distance–angle criterion; continuous structural descriptors calculated from OC2-generated covalently linked HER2–inhibitor structures were used to characterize structural differences after covalent linkage; and covalent-adduct MD trajectories were used to characterize post-bond-formation dynamics. The Michael-addition step itself was neither simulated nor measured. Cyclization of compound 3 to compound 9c increased the NAC-like frame fraction in HER2WT from 0.0217% to 0.358% but decreased it in HER2YVMA from 0.745% to 0.333%, with the direction preserved across all six sensitivity definitions. In HER2YVMA, the modification distinguishing compounds 4a and 5a increased the NAC-like fraction from 2.620% to 6.244% despite a loss of cellular potency. The analogous tail modification increased this fraction in the 8c/10e series but reduced it in the 9c/11f series. The distribution of OC2-generated covalently linked structures across the predefined structural coordinate and the final-adduct MD readouts likewise varied with HER2 context and scaffold, although some differential effects were sensitive to the coordinate reference. No single structural readout tracked endpoint potency across all six pairs. These analyses complement experimental SAR but do not provide a measure of reaction kinetics or thermodynamic populations.